Please assess the completion status of the following clinical trial:

Trial Title: PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>/= 18 years of age~* chronic hepatitis C~* HIV HCV co-infection allowed~* informed consent to data collection~Exclusion Criteria:~* co-infection with Hepatitis B Virus (HBV)~* previous treatment with peginterferon and/or ribavirin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort (Type: None): Participants chronically infected with the hepatitis C virus including genotypes 1 to 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).